At a glance
ClinicalIndex Comparison RecordN/ACompleted· 90 enrolled
Drug / intervention
postoperative hypofractionated stereotactic radiotherapyradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Prospective Phase II Study of Postoperative Hypofractionated Stereotactic Body Radiotherapy (SBRT) in the Treatment of Early Stage Oropharyngeal and Oral Cavity Cancers With High Risk Margins.
In Brief
A clinical study evaluating postoperative hypofractionated stereotactic radiotherapy for Head and Neck Neoplasms. Completed, enrolled 90 participants across 24 sites.
Detailed Summary
The main objective of this national, open-label, non-randomized phase II trial is to evaluate severe late toxicity of postoperative hypofractionated stereotactic radiotherapy (SBRT) in the treatment of early stage oropharyngeal and oral cavity cancer with high risk margins.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Neoplasms
CountriesFrance
CollaboratorsGORTEC
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartJan 2018
Primary CompletionSep 2023
TodayJul 2026
First PostedJan 17, 2018
Enrollment StartJan 23, 2018
Primary CompletionSep 28, 2023
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 8.5 years ago
Interventions
postoperative hypofractionated stereotactic radiotherapyradiation
total dose of 36Gy in 6 fractions over 11-13 days